MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-09-2022
Clovis Oncology P/E Ratio 2011-2026 | CLVS
Annual P/E Ratio Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.873 | -1.89 | -1.16 | -3.48 | -8.28 | -6.81 | -2.14 | -13.8 | -22.9 | -6.63 | -1.31 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.873 | -22.9 | -6.3 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Verastem
VSTM
|
-1.93 | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
-1.43 | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
-0.0465 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-41.7 | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenon Pharmaceuticals
XENE
|
-12.8 | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
-0.0138 | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
-0.649 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
-11.1 | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Bellerophon Therapeutics
BLPH
|
-3.96 | - | -74.18 % | $ 955 K | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
130 | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-25.3 | $ 4.29 | -3.6 % | $ 822 M | Canada |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-2 | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
-8.34 | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-14.6 | - | - | $ 1.41 B | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 19.01 | -2.66 % | $ 889 M | USA |
 |
Gritstone Oncology
GRTS
|
-1.99 | - | 0.42 % | $ 213 M | USA |
 |
Завод ДИОД
DIOD
|
17.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-3.81 | - | - | - | Russia |
 |
ACADIA Pharmaceuticals
ACAD
|
14.1 | $ 20.75 | -3.35 % | $ 3.44 B | USA |
 |
Aligos Therapeutics
ALGS
|
-2.73 | $ 6.66 | -5.4 % | $ 65.8 M | USA |
 |
Teligent, Inc.
TLGT
|
-0.879 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-2.83 | - | - | $ 2.91 B | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Alkermes plc
ALKS
|
21.2 | $ 29.39 | -1.77 % | $ 4.84 B |  Irlanda |
 |
Cabaletta Bio
CABA
|
-1.69 | $ 2.68 | -4.96 % | $ 269 M | USA |
 |
AbbVie
ABBV
|
220 | $ 209.4 | -0.81 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
-6.57 | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
ARCA biopharma
ABIO
|
-5.78 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-0.463 | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-4.26 | - | 4.01 % | $ 150 M | Canada |
 |
Athira Pharma
ATHA
|
-0.167 | - | - | $ 269 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | USA |